絞り込み

16555

広告

A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.

著者 Zhang F , Bae SC , Bass D , Chu M , Egginton S , Gordon D , Roth DA , Zheng J , Tanaka Y
Ann Rheum Dis.2018 Jan 02 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (38view , 0users)

Full Text Sources

Intravenous belimumab plus standard of care (SoC) is approved in the USA and Europe for treatment of active, autoantibody-positive systemic lupus erythematosus (SLE).
PMID: 29295825 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード